Rothschild Redburn upgrades Abbott Laboratories stock to Buy

Published on 10/07/2026 at 14:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter adjusted earnings per share reached USD 1.31. Abbott Laboratories stock costs EUR 87.94 on October 7, 2026 after EUR 87.55.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was trading at EUR 87.94 at Lang & Schwarz on October 7, 2026 at 2:20 p.m. CEST, up EUR 0.39 or 0.45 percent versus the prior close of EUR 87.55. Rothschild Redburn upgraded Abbott Laboratories from Neutral to Buy and raised its price target from USD 119.00 to USD 127.00 on October 2, 2026, according to Investing.com.

Target rises on device growth

Rothschild Redburn cited Abbott's Medical Devices business, which it expects to grow 10.60 percent organically in fiscal 2026. The firm also projected 11.70 percent growth for Abbott's diabetes technology segment in fiscal 2026, according to Investing.com.

The analyst report identified Abbott's cardiovascular and diabetes operations as growth supports, while also pointing to the acquisition of Exact Sciences as a boost for diagnostics. Its counter-factor was Abbott's conglomerate structure and the lower growth profile of nutrition activities.

Second-quarter numbers set the baseline

Abbott reported adjusted earnings per share of USD 1.31 and revenue of USD 12.59 billion in the second quarter of 2026, according to Investing.com. Revenue increased 13.00 percent year over year, giving the quarter a clear comparison point for the updated analyst view.

Abbott's adjusted earnings per share guidance for fiscal 2026 stands at USD 5.45 to USD 5.60. The company also maintained annual revenue growth expectations of 6.50 percent to 7.50 percent excluding foreign-currency effects, according to MarketBeat.

Stock remains below its yearly high

On the NYSE, Abbott was last at USD 98.17 on October 6, 2026 at 3:59 p.m. ET. The primary-exchange 52-week range was USD 81.97 to USD 135.13, while market capitalization was USD 169.9 billion as of October 6, 2026.

The company declared a quarterly dividend of USD 0.63 per share, payable November 16, 2026, with an ex-dividend date of October 15, 2026, according to MarketBeat. For investors, the key tension is visible in the combination of double-digit quarterly revenue growth and the analyst's call for sharper device-led expansion.

Euro quote holds above prior close

Abbott Laboratories stock was trading at EUR 87.94 at Lang & Schwarz on October 7, 2026 at 2:20 p.m. CEST, plus 0.45 percent versus the Lang & Schwarz prior close of EUR 87.55 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.